The United States' insufficient supply of H1N1 vaccines to inoculate our population demonstrates how poorly prepared we are to confront a pandemic.

We must make a concerted effort today to increase our capacity for timely development of safe, effective and innovative flu vaccines.

The development of antivirals for pandemic flu provides important insights into the pharmaceutical industry's ability to advance public health.

The Roberts Court's business cases suggest that it is finally stepping away from the culture wars and returning to the nuts and bolts of law.

Legislators should adopt policies that encourage companies to make vaccines more quickly and less expensively.

We have made progress in pandemic preparedness, but we have a long way to go in ensuring a vibrant and responsive vaccine sector.